HPGC: Lercanidipine tablets pass the consistency evaluation for generic drugs
HPGC announced that its subsidiary Harbin Pharmaceutical Group Sanjing Ming Shui Pharmaceutical Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, confirming that Lacidipine tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Lacidipine is an efficient calcium ion antagonist primarily used for dilating peripheral small arteries and lowering blood pressure, suitable for the treatment of hypertension
According to the announcement from Zhitong Finance APP, HPGC (600664.SH) has released a notice stating that its subsidiary, Harbin Pharmaceutical Group Sanjing Ming Shui Pharmaceutical Co., Ltd. (referred to as "Sanjing Ming Shui"), has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for Lercanidipine Tablets [No.: 2025B04172]. This product has passed the consistency evaluation of quality and efficacy for generic drugs.
Lercanidipine is a highly selective and effective calcium ion antagonist, with a high selectivity for calcium channels in vascular smooth muscle. Its main function is to dilate peripheral small arteries, reduce peripheral vascular resistance, and lower blood pressure. It can be used alone or in combination with other antihypertensive medications, such as β-blockers, diuretics, and angiotensin-converting enzyme inhibitors, to treat hypertension
